OVERVIEW OF THE PHARMACEUTICAL MARKET IN SAUDI ARABIA
Saudi Arabia' s transition to an increasingly privatised and comprehensive healthcare system will drive the demand for both patented and generic drugs. The country is investing heavily in healthcare infrastructure and we expect this will be borne out in double-digit growth forecasts across our three headline indicators.
Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis-details/the-pharmaceutical-market-saudi-arabia
Headline Expenditure Projections
Pharmaceuticals: SAR16.70bn (US$4.46bn) in 2011 to SAR18.95bn (US$5.06bn) in 2012; +13.5% in local currency and US dollar terms. Forecastbroadly unchanged from Q3 12. •
Healthcare: SAR78.63bn (US$21.00bn) in 2011 to SAR91.20bn (US$24.35bn) in 2012; +16.0% in local currency and US dollar terms. Forecast broadly unchanged from Q3 12. •
Medicaldevices: SAR5.54bn (US$1.48bn) in 2011 to SAR6.53bn (US$1.74bn) in 2012; +17.8% in local currency and US dollar terms. Forecastunchanged from Q3 12. Risk/Reward Rating
Saudi Arabia's composite score remained steady in Q4 12 at 55.6. This places the country to firth place out of the 30 markets in the region. Its score is propped up by the country's wealth and a sizeable population (exceeding 28mn in 2011). Furthermore, its forecast growth rate is high due to favourable public and private healthcare investments. The government is also in the process of creating more public-private health partnerships and encouraging private health insurance uptake, which should provide momentum for drug sales. To Get Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/193655
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Table of Contents
Please join StudyMode to read the full document